Last reviewed · How we verify

Thallous Chloride T1-201 — Competitive Intelligence Brief

Thallous Chloride T1-201 (Thallous Chloride T1-201) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cardiac imaging agent. Area: Cardiovascular.

marketed Cardiac imaging agent Na+/K+-ATPase pump Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Thallous Chloride T1-201 (Thallous Chloride T1-201) — GE Healthcare. Thallous chloride T1-201 is a potassium analog that accumulates in viable myocardial tissue and is used as a radiotracer for cardiac imaging.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Thallous Chloride T1-201 TARGET Thallous Chloride T1-201 GE Healthcare marketed Cardiac imaging agent Na+/K+-ATPase pump

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cardiac imaging agent class)

  1. GE Healthcare · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Thallous Chloride T1-201 — Competitive Intelligence Brief. https://druglandscape.com/ci/thallous-chloride-t1-201. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: